New search Hide text from Guidelines
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINSThis group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.
| The DDDs are generally based on the treatment or diagnosis of endocrine disorders. |
H05 CALCIUM HOMEOSTASIS
Drugs acting on calcium homeostasis are classified in this group.
Vitamin-D preparations, see A11CC.
H05B ANTI-PARATHYROID AGENTS
H05BA Calcitonin preparations
Calcitonin, natural and synthetic, is classified in this group. Other drugs for treatment of hypercalcemia, see M05B.
| The DDDs of the calcitonins are based on the treatment of Pagets disease. |
H05BX Other anti-parathyroid agents
Paricalcitol and doxercalciferol indicated for the prevention and treatment of secondary hyperparathyroidism are classified here.
Oral formulations of calcifediol, solely approved for treatment of renal secondary hyperparathyroidism are classified here, while all other pharmaceutical formulations of calcifediol are classified in A11CC06.
| The DDDs for cinacalcet and evocalcet are based on the treatment of secondary hyperparathyroidism. |
Last updated: 2024-01-26